Exciting news from RenovoRx overnight.Emphases are mine.Godspeed...

Exciting news from RenovoRx overnight.
Emphases are mine.
Godspeed Renovo.
IMO

MOUNTAIN VIEW, CA – March 26, 2025 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renovo Cath, a novel, FDA-cleared drug-delivery device, is proud to announce that a publication supporting the Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for targeted locoregional drug delivery will be recognized in the Journal of Vascular and Interventional Radiology (JVIR) Award-Winning Paper Scientific Session during the upcoming Society of Interventional Radiology (SIR) 2025 Annual Scientific Meeting. The peer-reviewed paper, published in the July 2024 edition of JVIR, is being honored during the conference’s JVIR Award-Winning Paper Scientific Session in Nashville, TN, scheduled at 3:00-4:30 PM CT on Tuesday, April 1, 2025. The session will be moderated by Daniel Sze, MD, PhD, Stanford University. This paper is one of nine 2024 JVIR papers to be awarded for outstanding laboratory investigation during the conference.

The JVIR Award-Winning Paper, titled “Double-Balloon Catheter–Mediated Trans arterial Chemotherapy Delivery in a Swine Model: A Mechanism Recruiting the Vasa Vasorum for Localized Therapies,” is authored by Khashayar Farsad, MD, PhD of the Department of Interventional Radiology at Oregon Health and Science University, and co-authored by Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, together with other researchers, including RenovoRx’s founder and Chief Medical Officer, Dr. Ramtin Agah. During JVIR Award-Winning Paper Scientific Session, Dr. Agah will present the findings of the paper.

We are deeply honored to be recognized for our research at SIR 2025 Annual Scientific Meeting in the JVIR Award-Winning Paper Scientific Session,” said Dr. Agah. “This recognition reflects RenovoRx’s innovation and treatment paradigm that may translate to benefits in treatment of patients with solid tumors. I look forward to presenting these findings at the upcoming conference, and my colleagues and I are grateful for this recognition and validation of our commitment to advancing the field of interventional oncology.”

Currently, most cancer patients with solid tumors receive chemotherapy intravenously, introducing the drug systemically into the entire body. This is well-known to cause adverse side effects. RenovoRx’s patented TAMP therapy platform is designed to bypass traditional systemic delivery methods and provide targeted delivery to bathe the target solid tumor in chemotherapy. This locoregional delivery also creates the potential to minimize a therapy’s systemic toxicities.The pre-clinical data published in JVIR showed a 100-fold (two orders of magnitude) increase in local tissue concentration of the therapy with TAMP compared to conventional intravenous (IV) delivery. TAMP also showed advantages compared to historically available intra-arterial (IA) delivery approaches. TAMP’s novel approach to treatment offers the potential to increase an oncology therapy’s efficacy, improve safety, and widen its therapeutic window by focusing its distribution uniformly in target tissue.“TAMP has the potential to provide a valuable treatment option to patients who have been diagnosed with solid tumors that may be difficult-to-treat,” said Dr. Farsad. “This platform also has the potential to extend across a variety of unmet needs for localized therapeutic drug delivery.

This study shows a possible mechanism for how TAMP can increase local therapeutic tissue concentration in solid tumors that is independent from traditional catheter-directed therapy. We are awaiting final outcomes from RenovoRx’s TIGeR-PaC Phase III clinical trial, currently underway, to further validate this benefit.”“We believe this award further supports our decision to accelerate the commercialization of our proprietary RenovoCath as a standalone device,” said Shaun Bagai, CEO of RenovoRx. “We are rapidly expanding efforts and forging stronger relationships with leading oncology centers nationwide who are using RenovoCath. This progress not only positions our company for growth but also reinforces our growing leadership in the oncology space, unlocking substantial value-creation opportunities. We continue to scale our commercialization efforts and, in tandem, progress our Phase III TIGeR-PaC trial in the most capital efficient manner.”

About RenovoCathBased on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
Abridged.

Back in July 2023
Los Altos, CA and Sydney, Australia, July 20, 2023 – RenovoRx, Inc. (“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd (“Imugene”) (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.“We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” said Leslie Chong, Managing Director & Chief Executive Officer of Imugene. “Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy,” said Shaun Bagai, Chief Executive Officer, RenovoRx. “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”
Ends